← All Janux Therapeutics, INC filings

Janux Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
JANX
Janux Therapeutics, INC
DEF: Janux Therapeutics Sets June 11, 2026 Annual Meeting Date
Janux Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, detailing proposals for director elections, auditor ratification, and executive compensation.
NASDAQ
JANX
Janux Therapeutics, INC
DEFA14A: Janux Therapeutics Sets Date for 2025 Annual Stockholders Meeting
Janux Therapeutics will hold its annual stockholders meeting on June 11, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.
NASDAQ
JANX
Janux Therapeutics, INC
DEF: Janux Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Janux Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.
NASDAQ
JANX
Janux Therapeutics, INC
DEFA14A: Janux Therapeutics Updates Non-Employee Director Compensation Policy
Janux Therapeutics amends and restates its non-employee director compensation policy, effective immediately, with changes to equity awards.
NASDAQ
JANX
Janux Therapeutics, INC
DEFA14A: Janux Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Janux Therapeutics will hold its annual stockholders meeting virtually on June 26, 2024, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.
NASDAQ
JANX
Janux Therapeutics, INC
DEF 14A: Janux Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Janux Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to elect directors and ratify the selection of its independent accounting firm.